These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35502101)

  • 1. Response to comment on: Effect of short-term meditation training in central serous chorioretinopathy.
    Venkatesh P; Surve A; Yadav R
    Indian J Ophthalmol; 2022 May; 70(5):1855. PubMed ID: 35502101
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to comment on: Effect of short-term meditation training in central serous chorioretinopathy.
    Venkatesh P; Surve A
    Indian J Ophthalmol; 2022 May; 70(5):1857. PubMed ID: 35502103
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment on: Effect of short-term meditation training in central serous chorioretinopathy.
    Panigrahi PK
    Indian J Ophthalmol; 2022 May; 70(5):1856. PubMed ID: 35502102
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on: Effect of short-term meditation training in central serous chorioretinopathy.
    Suryakanth S; Ramanjulu R; Shanmugam MP; Mishra DKC
    Indian J Ophthalmol; 2022 May; 70(5):1854. PubMed ID: 35502100
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of short-term meditation training in central serous chorioretinopathy.
    Nongrem G; Surve A; Venkatesh P; Sagar R; Yadav RK; Chawla R; Vohra R; Kumar A
    Indian J Ophthalmol; 2021 Dec; 69(12):3559-3563. PubMed ID: 34826995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reply to Comment on "Vigorous Physical Activity as a Risk factor for Central Serous Chorioretinopathy".
    Cardillo Piccolino F; Fruttini D; Eandi C; Nicolò M; Mariotti C; Tito S; Lupidi M
    Am J Ophthalmol; 2023 May; 249():185-186. PubMed ID: 36796661
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Comment on: Vigorous Physical Activity as a Risk factor for Central Serous Chorioretinopathy.
    Piccolino FC; Fruttini D; Eandi C; Nicolò M; Mariotti C; Tito S; Lupidi M
    Am J Ophthalmol; 2023 May; 249():189-190. PubMed ID: 36587714
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of choroidal thickness among patients with healthy eyes, early age-related maculopathy, neovascular age-related macular degeneration, central serous chorioretinopathy, and polypoidal choroidal vasculopathy.
    Kim SW; Oh J; Kwon SS; Yoo J; Huh K
    Retina; 2011 Oct; 31(9):1904-11. PubMed ID: 21878855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we classify central serous chorioretinopathy better? Yes we can.
    Lotery A
    Eye (Lond); 2022 Mar; 36(3):487. PubMed ID: 34645968
    [No Abstract]   [Full Text] [Related]  

  • 10. Commentary: Retinal pigment epithelial leak identification in central serous chorioretinopathy: Is fundus fluorescein angiography a must?
    Delhiwala K; Khamar B
    Indian J Ophthalmol; 2022 Mar; 70(3):895-896. PubMed ID: 35225538
    [No Abstract]   [Full Text] [Related]  

  • 11. Commentary: Available evidence on early treatment of central serous chorioretinopathy.
    Tripathy K; Mishra C; Addya S
    Indian J Ophthalmol; 2021 Sep; 69(9):2348-2349. PubMed ID: 34427219
    [No Abstract]   [Full Text] [Related]  

  • 12. Light exposure in acute central serous chorioretinopathy.
    Norouzpour A
    Eye (Lond); 2022 Jan; 36(1):243. PubMed ID: 33423042
    [No Abstract]   [Full Text] [Related]  

  • 13. Salivary Alpha-Amylase Levels May Correlate With Central Serous Chorioretinopathy Activity.
    Abdelhakim AH; Ledesma-Gil G; Yannuzzi LA
    Retina; 2021 Oct; 41(10):2007-2008. PubMed ID: 34292223
    [No Abstract]   [Full Text] [Related]  

  • 14. Anxiolytics in the treatment of central serous chorioretinopathy.
    Dudani AI; Dudani A; Dudani K; Dudani A
    Indian J Ophthalmol; 2022 Feb; 70(2):701. PubMed ID: 35086281
    [No Abstract]   [Full Text] [Related]  

  • 15. Anxiolytics in the treatment of central serous chorioretinopathy.
    Dudani AI; Dudani A; Dudani K; Dudani A
    Indian J Ophthalmol; 2021 Oct; 69(10):2902-2903. PubMed ID: 34571681
    [No Abstract]   [Full Text] [Related]  

  • 16. Commentary: Acute central serous chorioretinopathy - Treat early, observe longer.
    Kumar N; Parachuri N; Sharma A
    Indian J Ophthalmol; 2021 Sep; 69(9):2347-2348. PubMed ID: 34427218
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on: Traumatic central serous chorioretinopathy.
    Agarwal M; Singh S; Mayor R; Venkatesh R
    Indian J Ophthalmol; 2015 Nov; 63(11):872-3. PubMed ID: 26669347
    [No Abstract]   [Full Text] [Related]  

  • 18. Anxiolytics and psychotropic medications in central serous chorioretinopathy: Caveats and concerns.
    Jain M
    Indian J Ophthalmol; 2022 Feb; 70(2):700-701. PubMed ID: 35086280
    [No Abstract]   [Full Text] [Related]  

  • 19. Retinal microstructural abnormalities in central serous chorioretinopathy and polypoidal choroidal vasculopathy.
    Ooto S; Tsujikawa A; Mori S; Tamura H; Yamashiro K; Otani A; Yoshimura N
    Retina; 2011 Mar; 31(3):527-34. PubMed ID: 20890237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: Traumatic central serous chorioretinopathy.
    Takkar B; Azad S
    Indian J Ophthalmol; 2016 Feb; 64(2):166-7. PubMed ID: 27050359
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.